Mark Roeser headshot

Mark E. Roeser

Associate Professor
Unit: School of Medicine
Department: Department of Surgery
Office location and address
81 Hospital Dr
Charlottesville, Virginia 22903
University of Texas Southwestern Medical School, MD
Residency, University of Texas Southwestern Medical School; University of Virginia
Fellowship, Texas Children's Hospital

Mark Roeser, MD, was born with congenital heart disease and has a close connection with his patients. His specific diagnosis is Tetralogy of Fallot, and he had corrective surgery at 20 months of age. He later attended the University of Texas at Austin and continued to the University of Texas Southwestern Medical School, where he was elected AOA (top 10 percent of medical students, nationwide.) He completed his general surgery residency at UTSW at Parkland Hospital and his thoracic surgery residency at UVA. He completed his training with a congenital heart surgery fellowship at Texas Children’s Hospital.

Dr. Roeser returned to UVA in 2015 and operates on people with congenital heart defects of all ages and diagnoses. Most notably, he has performed the first bilateral pediatric lung transplant for pulmonary hypertension in the state of Virginia, the first successful Berlin heart LVAD, the first successful Berlin heart BiVAD, and the first successful pediatric Heartware HVAD in the state of Virginia.

Dr. Roeser’s research emphasis is on treating ischemia reperfusion injury in ECMO patients. He is working to expand the lung donor pool, by rehabbing donor lungs outside the body. Dr. Roeser has combined these two techniques and has developed a porcine model that is able to rehab lungs affected by sepsis inside the body. He is also developing a stent that can be placed inside the heart to make mechanical assist devices more efficient and easier to manage long term.

Dr. Roeser is a father of three active children. He likes to surf, snowboard and study history. He loves his job and considers it a privilege to help his patients thrive as survivors of congenital heart disease.

The Next Step: Regadenoson mitigates ischemia reperfusion injury and is renal protective in a 48 hour porcine model of resuscitative ECMO
Source: U.S. NIH Heart, Lung, And Blood Institute
May 09, 2019 – April 30, 2024
VADStent to Prevent Cavity Collapse and Adverse Cardiac Remodeling
Source: Virginia Innovation Partnership Corporation
June 17, 2019 – June 30, 2021
MD-SURG Attenuation of Ischemia Reperfusion Injury after E-CPR with Selective Adenosine Agonist
Source: Extracorporeal Life Support Organization
July 01, 2016 – June 30, 2017